MedTrace Logo

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

NCT02495844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2019-02-05

Study results available
· View outcomes & findings →

Summary

This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.

Conditions

  • Highly Drug-resistant Focal Epilepsy

Interventions

DRUG

UCB0942

Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use

DRUG

UCB0942

Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use

DRUG

Placebo

Pharmaceutical form: Film-coated tablet Route of administration: Oral use

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • UCB Biopharma S.P.R.L.

    lead INDUSTRY

Principal Investigators

  • UCB Cares · +1 844 599 2273 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-02-28
Completion
2017-07-31

Countries

  • Belgium
  • Bulgaria
  • Germany
  • Hungary
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02495844 on ClinicalTrials.gov